Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Biodel Inc., a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes, has signed a long-term manufacturing agreement with Cangene bioPharma Inc., a wholly-owned subsidiary of Emergent BioSolutions (Emergent) for development of its Glucagon Emergency Management (GEM) programme.
Under the agreement, Emergent will fill and finish commercial quantities of the GEM device. Financial terms of the agreement have not been disclosed.
The GEM device, to which Biodel holds exclusive rights for use with glucagon, is a customized version of Unilife's dual-chamber auto-reconstitution syringe. GEM is being developed for use as a rescue treatment for severe hypoglycemia. GEM is an intuitive, easy-to-use device designed to address and expand a market underserved by the currently available kits that are difficult to assemble and operate during an emergency.
http://www.pharmabiz.com/NewsDetails.aspx?aid=80806&sid=2
Under the agreement, Emergent will fill and finish commercial quantities of the GEM device. Financial terms of the agreement have not been disclosed.
The GEM device, to which Biodel holds exclusive rights for use with glucagon, is a customized version of Unilife's dual-chamber auto-reconstitution syringe. GEM is being developed for use as a rescue treatment for severe hypoglycemia. GEM is an intuitive, easy-to-use device designed to address and expand a market underserved by the currently available kits that are difficult to assemble and operate during an emergency.
http://www.pharmabiz.com/NewsDetails.aspx?aid=80806&sid=2